The Zebrafish Centre for Advanced Drug Discovery is home to the first automated high-throughput zebrafish screening facility in Canada and one of the most advanced screening facilities worldwide. A major infrastructure award from the Canada Foundation for Innovation enabled the centre to build a robotic drug screening platform for zebrafish embryos. The Zebrafish Centre for Advanced Drug Discovery performs robotic, fully automated screens for zebrafish embryos, which include embryo sorting, incubation, drug dosing and efficacy readout, controlled by robotic arms and software.
Over the past five years, the Zebrafish Centre for Advanced Drug Discovery’s research spectrum has grown tremendously. In collaboration with other institutions, the Zebrafish Centre for Advanced Drug Discovery has developed a unique zebrafish based drug discovery pipeline, which is serving over 40 zebrafish disease modeling and drug screening projects.
Besides the CFI infrastructure funding, the Zebrafish Centre for Advanced Drug Discovery has successfully obtained three major operating grants including a grant from the Brain Canada Foundation to establish the Z-BRAIN Platform for neurological diseases, a grant from OCE-CQDM to support screening system automation, and most recently a Genome Canada GAPP grant in support of preclinical development of anti-stroke drugs. Our industrial partners include Edge Therapeutics, Eli Lilly, Treventis Corp, Autka Inc , Life Chemicals and Ultragenyx Pharmaceutical.